3rd Quarter - Report

PERSONALIZED MEDICINE COALITION for PERSONALIZED MEDICINE COALITION

Firm
Client
Income
—
Expenses
$43,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Congressional Personalized Medicine Caucus Senate Rapid Artificial Intelligence (AI) Forum Response to Request for Information: Commonsense Policy Options to Lower Drug Prices for Patients Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions [CMS-4215-P] Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1848-P] Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program Proposed Rule for Calendar Year 2027 [CMS-1850-P] Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance [FDA-2026-D-1257] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

LobbyistCovered position, as disclosed
CYNTHIA BENS Staff, Representative Paul E. Kanjorski

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Budget/Appropriations BUD

FY 2027 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2027 National Institutes of Health Budget Priorities Reauthorization of the Prescription Drug User Fee Amendments; PFUFA VIII Reauthorization of the Medical Device User Fee Amendments; MDUFA VI ; Request for Comments [FDA-2026-N-6655] Revising Federal Grant Administration and Uniform Guidance [OMB-2026-0034]

LobbyistCovered position, as disclosed
CYNTHIA BENS Staff, Representative Paul E. Kanjorski

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.